These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Lack of evidence that the central serotoninergic system plays a role in the activation of prolactin secretion following inhibition of dopamine synthesis or blockade of dopamine receptors in the male rat. Krulich L; Coppings RJ; Giachetti A; McCann SM; Mayfield MA Neuroendocrinology; 1980; 30(3):133-8. PubMed ID: 6445044 [TBL] [Abstract][Full Text] [Related]
5. Brainstem auditory evoked responses in progressive supranuclear palsy. Tolosa ES; Zeese JA Ann Neurol; 1979 Oct; 6(4):369. PubMed ID: 554529 [No Abstract] [Full Text] [Related]
8. [Progressive supranuclear palsy: a case report and etiological study of eye movement disturbance]. Kawamura Y; Shibazaki H; Shida K; Goto I; Kuroiwa Y Rinsho Shinkeigaku; 1975 Aug; 15(8):535-40. PubMed ID: 1237380 [No Abstract] [Full Text] [Related]
9. A case of progressive supranuclear palsy--neurotological findings and etiology. Umeda Y; Sakata E J Otolaryngol; 1978 Oct; 7(5):409-14. PubMed ID: 739573 [TBL] [Abstract][Full Text] [Related]
10. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Kish SJ; Chang LJ; Mirchandani L; Shannak K; Hornykiewicz O Ann Neurol; 1985 Nov; 18(5):530-6. PubMed ID: 2416269 [TBL] [Abstract][Full Text] [Related]
11. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Baron JC; Maziere B; Loc'h C; Sgouropoulos P; Bonnet AM; Agid Y Lancet; 1985 May; 1(8438):1163-4. PubMed ID: 2860368 [No Abstract] [Full Text] [Related]
12. Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. Baron JC; Mazière B; Loc'h C; Cambon H; Sgouropoulos P; Bonnet AM; Agid Y J Cereb Blood Flow Metab; 1986 Apr; 6(2):131-6. PubMed ID: 3485639 [TBL] [Abstract][Full Text] [Related]
13. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Jackson JA; Jankovic J; Ford J Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139 [TBL] [Abstract][Full Text] [Related]
14. Progressive supranuclear palsy: the relationship between ocular motor dysfunction and psychological test performance. Fisk JD; Goodale MA; Burkhart G; Barnett HJ Neurology; 1982 Jul; 32(7):698-705. PubMed ID: 7201107 [TBL] [Abstract][Full Text] [Related]
15. Progressive supranuclear palsy: postmortem chemical analysis. Young AB Ann Neurol; 1985 Nov; 18(5):521-2. PubMed ID: 2866753 [No Abstract] [Full Text] [Related]
16. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Rafal RD; Grimm RJ Neurology; 1981 Dec; 31(12):1507-18. PubMed ID: 7198201 [TBL] [Abstract][Full Text] [Related]
18. [Therapy of progressive supranuclear paralysis. Effect of methysergide and bromocriptine on various psychoneurologic and motor functions]. Giménez-Roldán S; de Andrés C; Salinero E Rev Clin Esp; 1979 Apr; 153(1):21-7. PubMed ID: 461893 [No Abstract] [Full Text] [Related]
19. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. Neophytides A; Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Bock J; Walker R J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):261-3. PubMed ID: 7086448 [TBL] [Abstract][Full Text] [Related]